Siliq Market Report 2026

Siliq Market Overview

• The Siliq market growth in the historic period has been driven by increasing prevalence of moderatesevere plaque psoriasis, limited efficacy of conventional systemic therapies • Market expansion is supported by increasing demand for next-generation biologics, rising focus on long-term disease management • Growth Driver: Impact Of Rising Skin Disease Prevalence On The Market Growth • North America was the largest region and fastest growing region.

What Is Covered Under Siliq Market?

Siliq refers to a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The mechanism of action involves its targeting and inhibition of the IL-17A receptor. IL-17A is a pro-inflammatory cytokine that plays a crucial role in the development of inflammation in conditions like plaque psoriasis. The main types of clinical indications for siliq include moderate-to-severe plaque psoriasi and others. Moderate to severe plaque psoriasis refers to a chronic skin condition characterized by red, inflamed patches covered with silvery-white scales and Siliq, a biologic therapy, is specifically designed to treat moderate to severe plaque psoriasis by targeting and inhibiting the interleukin-17 receptor, helping to reduce inflammation and plaque formation in affected patients. The distribution channels are categorized into hospital pharmacies, retail pharmacies, specialty pharmacies and various end users include hospitals, specialty clinics, and home care settings.

What Is The Siliq Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for next-generation biologics, rising focus on long-term disease management, expansion of personalized immunology treatments, growing investments in inflammatory disease research, increasing patient access to specialty therapies. Major trends in the forecast period include increasing adoption of targeted biologic therapies, growing use of il-17 pathway inhibitors, rising focus on personalized psoriasis treatment, expansion of specialty pharmacy distribution, enhanced monitoring of treatment outcomes.

Global Siliq Market Segmentation

1) By Clinical Indication: Moderate To Severe Plaque Psoriasis, Other Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies 3) By End-User: Hospitals, Specialty Clinics, Home Care Settings

What Are The Drivers Of The Siliq Market?

The increase in the prevalence of skin disease propels the growth of the siliq market going forward. Skin disease refers to a broad range of conditions that affect the skin's structure, function, or appearance, often caused by infections, inflammation, genetic factors, autoimmune disorders, or environmental influences. The increase in the prevalence of skin disease is attributed to factors such as environmental changes, rising pollution levels, increased sun exposure, genetic predispositions, and lifestyle factors like poor diet and stress. Siliq is beneficial for skin disease, particularly moderate to severe plaque psoriasis, as it targets specific immune system pathways to reduce inflammation, improve skin appearance, and alleviate symptoms such as redness, scaling, and itching. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization focused on cancer elimination, projected 108,270 reported cases of skin cancer, marking a 3.2% increase from the 104,930 cases recorded in 2023. Therefore, the increase in the prevalence of skin disease is fueling the growth of the siliq industry. The growing geriatric population is anticipated to drive the growth of the Siliq market in the future. The geriatric population refers to individuals who are typically 65 years or older, although this age threshold can vary depending on the context or healthcare standards. The geriatric population is increasing due to rising life expectancy, advancements in healthcare, and declining birth rates, leading to a larger proportion of older individuals globally. Siliq is beneficial for the geriatric population as it provides an effective treatment option for moderate to severe plaque psoriasis, helping to manage symptoms and improve skin health in older adults who may experience limited treatment options due to age-related health concerns. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, the UK had 12.7 million individuals aged 65 and above, making up 19% of the total population. By 2072, this number is expected to increase to 22.1 million, or 27% of the population. Therefore, the growing geriatric population is driving the growth of the siliq industry. The growing emphasis on precision medicine is projected to boost the growth of the siliq market. Precision medicine refers to a personalized approach to healthcare that tailors treatments based on an individual's genetic, environmental, and lifestyle factors. The growing emphasis on precision medicine is attributed to advancements in genetic research, increased understanding of personalized treatments, and the potential for improved patient outcomes through targeted therapies. Siliq is beneficial for precision medicine as it provides targeted treatment for moderate to severe plaque psoriasis by specifically inhibiting the IL-17A pathway, allowing for personalized and more effective therapy based on individual patient needs. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for rare diseases, marking a notable rise from just six approvals in 2022. Therefore, the growing emphasis on precision medicine will drive the growth of the siliq industry.

Key Players In The Global Siliq Market

Major companies operating in the siliq market are Valeant Pharmaceuticals International Inc.

Regional Insights

North America was the largest region in the siliq market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Siliq Market?

The siliq market consists of sales of single-dose prefilled syringes and single-dose prefilled autoinjectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Siliq Market Report 2026?

The siliq market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the siliq industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.